Skip to main content

Drug Interactions between lenvatinib and Primethasone

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dexAMETHasone lenvatinib

Applies to: Primethasone (dexamethasone) and lenvatinib

Consumer information for this interaction is not currently available.

MONITOR: Lenvatinib use in combination with or after recent use of other medications associated with osteonecrosis of the jaw (ONJ) may increase the risk of this rare side effect. Theories as to how ONJ develops include inhibition of bone remodeling, inflammation or infection, angiogenesis inhibition, innate or acquired immune dysfunction, as well as genetic predisposition; however, the pathophysiology is likely related to multiple factors. Medication-related ONJ (MRONJ) is a rare, but severe and debilitating condition whose exact cause remains unknown. Known risk factors for MRONJ include cancer, duration of antiresorptive therapy, dentoalveolar operations (such as tooth extraction), preexisting inflammatory dental disease, and concurrent use of multiple medications associated with a risk of ONJ (such as bisphosphonates, denosumab, romosozumab, angiogenesis inhibitors, and corticosteroids).

MANAGEMENT: Caution is advised when lenvatinib is used with other agents that are also associated with the development of ONJ. A routine oral examination should be performed prior to initiation of either treatment. Patients should be advised regarding good oral hygiene practices and to have regular preventive dentistry performed throughout treatment. For patients requiring invasive dental procedures, discontinuation of lenvatinib may be recommended. Patients should be advised to seek medical attention if they experience signs and symptoms of ONJ, such as: pain in the mouth, teeth, or jaw; swelling or sores inside the mouth; numbness or a feeling of heaviness in the jaw; loosening of a tooth; or exposure of bone in the jaw. Those who are suspected of having or who develop ONJ during lenvatinib therapy should receive care by a dentist or an oral surgeon. In all circumstances involving MRONJ, clinical judgment and a risk-benefit assessment should guide the management plan of each patient based on their specific clinical circumstances.

References

  1. "Product Information. Lenvima (lenvatinib)." Eisai Inc (2015):
  2. Zhang X, Hamadeh IS, Song S "Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS) https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.2693"
  3. Rosella D, Papi P, Giardino R "Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820581/"
  4. AIDhalaan NA, BaQais A, Al-Omar A "Medication-related Osteonecrosis of the Jaw: A Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067354/"
  5. Ruggiero SL, Dodson TB, Aghaloo T "Medication-Related Osteonecrosis of the Jaw - 2022 Update https://www.aaoms.org/docs/govt_affairs/advocacy_white_papers/mronj_position_paper.pdf"
View all 5 references

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.